SCHEMBL30697116

SCHEMBL30697116

CC(C)(C)OC(=O)N1CCN(c2ccc(S(=O)(=O)N3CCC(Nc4ncc(C(F)(F)F)c(O[C@H]5CCOC5)n4)CC3)cc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MERTK Q12866 3/20 0.44
ALK Q9UM73 2/20 0.43
CDK2 P24941 2/20 0.41
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41
CCNE1 P24864 1/20 0.41
GPR119 Q8TDV5 6/20 0.41
AXL P30530 1/20 0.40
TYRO3 Q06418 1/20 0.40
EGFR P00533 1/20 0.40
F13A1 P00488 1/20 0.40
TGM2 P21980 1/20 0.40
TGM1 P22735 1/20 0.40
SYK P43405 1/20 0.39
IKBKB O14920 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
CCR6 P51684 1/20 0.39
KDR P35968 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26919173 0.91 AXL (0.43) MERTKCDK2CDK1CCNB1CCNE1
SCHEMBL26919164 0.91 AXL (0.43) MERTKCDK2CDK1CCNB1CCNE1
SCHEMBL29763036 0.91 AXL (0.43) MERTKCDK2CDK1CCNB1CCNE1
SCHEMBL26944092 0.89 IKBKB (0.47) MERTKCDK2CDK1CCNB1CCNE1
SCHEMBL30496642 0.88 MERTK (0.41) MERTKCDK2CDK1CCNB1CCNE1
SCHEMBL30697139 0.87 IDH1 (0.44) ALKCDK2CDK1CCNB1CCNE1
SCHEMBL26943178 0.87 CDK2 (0.44) MERTKCDK2CDK1CCNB1CCNE1
SCHEMBL26943177 0.87 CDK2 (0.43) MERTKCDK2CDK1CCNB1CCNE1
SCHEMBL26943302 0.86 IKBKB (0.45) MERTKCDK2CDK1CCNB1CCNE1
SCHEMBL26943284 0.86 CDK2 (0.41) MERTKCDK2CDK1CCNB1CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250009745-A1 CDK INHIBITOR SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) 2025-01-09 US disclosed
EP-4289835-A1 CDK INHIBITOR Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2023-12-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250009745-A1 CDK INHIBITOR CDK9, CDKL1, CDK6 MERTK 3148/4885ALK 3371/4885CDK2 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.